LivioM Obtains Australian Patent for Microbiome Therapeutic 'LIV001'

Medytox Affiliate Livium
Completes Preclinical Trials and Production of Clinical-Grade Drugs
Obtains US Patent for New Drug Development Platform 'eLBP'

Microbiome-based new drug development company LivBiome announced on the 18th that it had obtained an Australian patent for the microbiome therapeutic 'LIV001' on the 17th. LivBiome is an affiliate of Medytox.

Livieom CI. [Photo by Livieom]

With this patent acquisition, LivBiome has secured exclusive rights to develop drugs similar to 'LIV001,' which is being developed as a treatment for inflammatory bowel disease. This patent was first registered in Korea in 2021 and is also pending application and registration in several overseas countries besides Australia.

LIV001 is being developed by LivBiome as a treatment for inflammatory bowel disease using the eLBP platform, which applies gene editing technology to existing microbiome technology. To enter global clinical trials, preclinical safety tests were conducted last year at a Good Laboratory Practice (GLP) institution, and clinical-grade drug production has been completed in collaboration with global Contract Development and Manufacturing Organizations (CDMOs). LivBiome plans to initiate global Phase 1 clinical trials in the second half of this year once the clinical approval process is completed as scheduled.

Additionally, LivBiome announced that it has obtained a U.S. patent for its microbiome therapeutic development platform 'eLBP.' LivBiome possesses a dual LBP platform for developing microbiome new drugs targeting intractable immune diseases and solid tumors. The eLBP platform includes proprietary engineering technology that is universal and efficient, and the company explained that it employs a technology protection strategy through patent applications. With the acquisition of the U.S. patent, LivBiome now holds exclusive rights to this technology, enabling active expansion of its pipeline and technology development.

Song Ji-yoon, CEO of LivBiome, stated, "LIV001, developed using the eLBP platform, is a microbial gene therapy and next-generation microbiome therapeutic that introduces target genes critical for therapeutic efficacy into microbes to enhance treatment effects and drug properties for immune diseases. We have completed the production of clinical-grade drugs to develop it as a treatment for inflammatory bowel disease and are fully prepared for global clinical entry. We will concentrate all our capabilities to deliver results that meet market expectations."